Frontiers journals are at the top of citation and impact metrics
The section Hypertension welcomes articles on key findings of basic and clinical aspects of blood pressure regulation, both systemic and in the pulmonary vascular bed, as well as novel data on genetic features, molecular mechanisms, pathophysiology, diagnosis, and treatment of high blood pressure.
Frontiers in Cardiovascular Medicine has a specialty section on Hypertension, which is devoted to publishing high-rank basic and clinical research in the field of the most prevalent cardiovascular risk factor, i.e. high blood pressure.
In the past forty years, the investigation of the mechanisms regulating blood pressure has been instrumental for improving our understanding of cardiovascular pathophysiology at large. This has led to a flood of knowledge with enormous implications for several other cardiovascular diseases, including heart failure, atherosclerosis, stroke, diabetes and renal diseases. Unfortunately, often the publication of relevant new findings has been hampered and/or delayed by a number of factors, and some important studies eventually did not get published. We intend to overcome these difficulties by ensuring an unbiased and swift assessment of all submitted manuscripts.
Hence, we encourage submissions reporting key findings on basic and clinical aspects of hypertension. The Hypertension section is open to all novel data concerning genetic, immunological or molecular mechanisms of blood pressure regulation and the development of hypertension. This section is also interested in receiving manuscripts on new information regarding the epidemiology, the diagnosis, the treatment and the prevention of the complications of hypertension such as cardiac, cerebral, vascular and renal organ damages induced by a persistently elevated blood pressure.
The Editors of the Hypertension section will be glad to receive Original Research Articles, Reviews, Mini-Reviews dealing with the various aspects of hypertension and related diseases. Case Reports are also permitted provided they convey an original message such as a new mechanism, a new therapeutic approach, etc. We would be particularly happy to receive articles reporting results from clinical investigations, including Phase I-III trials and population studies. Articles related to non-pharmacological management of hypertension, medical education and adherence or the development of new techniques to lower blood pressure will also be considered.
Indexed in: PubMed, PubMed Central, Google Scholar, DOAJ, CrossRef, Semantic Scholar, Ulrich's Periodicals Directory, ESCI, CLOCKSS
PMCID: all published articles receive a PMCID
Hypertension welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, General Commentary, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Review, Study Protocol and Systematic Review.
All manuscripts must be submitted directly to the section Hypertension, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Hypertension will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Cardiovascular Medicine.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com